NeuroRx, Inc.   Report issue

For profit Phase 3
Founded: Wilmington DE United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2017
NCT02974010
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

NeuroRx | NeuroRx, Inc. | VP Clinical Development, NeuroRx

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Bipolar Disorder (Phase 3)

Coronavirus Infections (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Dyspnea (Phase 3)

Lung Injury (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Suicidal Ideation (Phase 3)

Suicide (Phase 3)

Suicide, Attempted (Phase 3)

Syndrome (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 6